The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. https://nicoleytzr918976.levitra-wiki.com/1989796/glp_3_retatrutide_a_comparative_analysis